Publications by authors named "Ronald Kates"

Claim this Profile
A
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
Oleg Gluz, Ronald Kates, Sherko Kuemmel, Ulrike Nitz, Nadia Harbeck

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, Matthias Christgen, Sherko Kuemmel, Ronald Kates

JCO Clin Cancer Inform· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.
Guokun Zhang, Vindi Jurinovic, Stephan Bartels, Matthias Christgen, Henriette Christgen, Ronald E Kates

J Clin Invest· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiative.
Lisa Hirschberg, Franziska Henze, Kerstin Paradies, Sophie Winkler, Timo Schinköthe, Ronald Kates

Eur J Oncol Nurs· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Ronald E Kates

JAMA Netw Open· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Impact of Adaptive Progressive Supervised Resistance Training on Strength and Quality of Life in Patients with Breast Cancer during Chemotherapy: The VALESCO Study.
Lars Gerland, Nadia Harbeck, Susanne Frisse, Wilhelm Bloch, Wolfram Malter, Ronald Kates

Oncol Res Treat· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy.
Nadia Harbeck, Ronald Kates, Timo Schinköthe, Johannes Schumacher, Rachel Wuerstlein

Cancer Treat Rev· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Nadia Harbeck, Ulrike A Nitz, Matthias Christgen, Sherko Kümmel, Michael Braun, Ronald Kates

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Oleg Gluz, Ulrike A Nitz, Matthias Christgen, Sherko Kuemmel, Johannes Holtschmidt, Ronald E Kates

JAMA Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Tom Degenhardt, Peter A Fasching, Diana Lüftner, Volkmar Müller, Christoph Thomssen, Ronald E Kates

Trials· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Ronald Kates

Clin Cancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Ronald Kates

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald Kates

Breast Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
Ulrike A Nitz, Oleg Gluz, Sherko Kümmel, Matthias Christgen, Michael Braun, Ronald E Kates

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Amelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, Ulrike Nitz, Brigitte Rack, Ronald Kates

Br J Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Ulrike Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Kuemmel, Ronald Kates

Lancet Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Isabel Grote, Stephan Bartels, Leonie Kandt, Laura Bollmann, Henriette Christgen, Ronald Kates

Cancer Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet.
Cornelia Kolberg-Liedtke, Rachel Wuerstlein, Oleg Gluz, Florian Heitz, Muriel Freudenberger, Ronald E Kates

Breast Care (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Nadia Harbeck, Raquel von Schumann, Ronald Ernest Kates, Michael Braun, Sherko Kuemmel

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer.
Hua Ni, Jörg Kumbrink, Doris Mayr, Alina Seiler, Friederike Hagemann, Ronald Kates

J Pers Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Monika Graeser, Friedrich Feuerhake, Oleg Gluz, Valery Volk, Michael Hauptmann, Ronald Kates

J Immunother Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer surgery with augmented reality.
Pedro F Gouveia, Joana Costa, Pedro Morgado, Ronald Kates, David Pinto

Breast· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Rachel Wuerstlein, Nadia Harbeck, Eva-Maria Grischke, Dirk Forstmeyer, Raquel von Schumann, Ronald E Kates

Breast Care (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Matthias Christgen, Oleg Gluz, Nadia Harbeck, Ronald E Kates, Mieke Raap

Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ulrike Nitz, Oleg Gluz, Hans H Kreipe, Matthias Christgen, Sherko Kuemmel, Ronald E Kates

Ther Adv Med Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis